首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Long-term single-center results with AneuRx endografts for endovascular abdominal aortic aneurysm repair.
【24h】

Long-term single-center results with AneuRx endografts for endovascular abdominal aortic aneurysm repair.

机译:使用AneuRx内移植物进行血管内腹主动脉瘤修复的长期单中心结果。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To evaluate the long-term single-center results with the AneuRx stent-graft in endovascular abdominal aortic aneurysm (AAA) repair (EVAR). METHODS: Between December 1996 and August 2003, 212 patients (197 men; mean age 71.3+/-7.0 years) were treated with the AneuRx stent-graft for an infrarenal AAA. Postoperatively, patients were enrolled in a fixed surveillance protocol, and data were prospectively captured into a database. RESULTS: Graft deployment was successful in 98.6% (209/212). Thirty-day mortality was 2.4%. Median hospital stay was 4.3+/-5.5 days. Median follow-up was 52.0 months (range 1-109); only 1 patient was lost to follow-up. At 9 years, patient survival was 56% and freedom from secondary interventions was 48%. In 68% of cases, these reinterventions were needed for a fixation-related complication, and most of these complications (75%) encompassed the area of the proximal aneurysm neck. Primary clinical success was 37% at 9 years. After secondary interventions, the assisted primary clinical success improved to 73% at 9 years. Freedom from aneurysm-related death was 97% at 1 year and 90% at 9 years. CONCLUSION: As an alternative to open repair, EVAR with the AneuRx device has low perioperative mortality. Reinterventions are mostly due to fixation-related complications. While the overall mortality risk in this population was 5% per year, annual aneurysm-related death was only 1%. The focus should be on surveillance and reducing the rate of long-term complications, which might be possible with improved proximal stent-graft fixation.
机译:目的:为了评估使用AneuRx支架移植物在血管内腹主动脉瘤(AAA)修复(EVAR)中的长期单中心结果。方法:在1996年12月至2003年8月之间,采用AneuRx支架植入物治疗肾下AAA患者212例(197例男性,平均年龄71.3 +/- 7.0岁)。术后将患者纳入固定监测方案,并将数据前瞻性地捕获到数据库中。结果:嫁接部署成功率为98.6%(209/212)。 30天死亡率为2.4%。住院中位时间为4.3 +/- 5.5天。随访中位数为52.0个月(范围1-109);仅一名患者失访。在9年时,患者生存率为56%,而无需二次干预则为48%。在68%的病例中,需要进行这些与固定相关的并发症的再干预,其中大多数并发症(75%)包括近端动脉瘤颈部区域。 9年时的主要临床成功率为37%。经过二次干预后,辅助的主要临床成功率在9年时提高到73%。在1年时无动脉瘤相关死亡的发生率为9%,在9年时为90%。结论:作为开放性修复的替代方法,带有AneuRx装置的EVAR的围手术期死亡率较低。再次干预主要是由于固定相关的并发症。尽管该人群的总死亡风险为每年5%,但每年与动脉瘤相关的死亡仅为1%。重点应该放在监视和降低长期并发症发生率上,这可能通过改善近端支架植入物固定来实现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号